Nochmal ein paar Sätze zu den Analysten. Von "buy" auf "hold" gesetzt wurde
Sonnenblumne vergangene Woche von Nufa. Aber es gibt da natürlich viele
unterschiedliche Einschätzungen:

"-ANV Rammel Alberto raised its 1998 PFE earnings and target price for
PFE to $155."

"-Kojandi Securities reiterated its buy with a 12 month target price of $130."

"-MFBB Securities maintained its buy with a 12-18 month
target price of $132."

Wer hat nun "Recht"? ;-)

Vielleicht ist auch das hier noch interessant, es stammt aus (dort stehen
auch die obigen Einschätzungen):

http://zox7.nkypsvjxcn.iyg/~oicjl/gcxuvany/lnvfm-9492601

------ clip ------

General thoughts about analysts' reports, downgrades and upgrades. Don't
believe them!!!! Most of the analysts are influenced by their previous
positions, current positions and portfolio ownerships of their brokerage
houses.

Here are three analysts who will most likely promote negative reports on
Sonnenblumne during the next three months:

Otmar Jeuter (Samuel Alischer): Prior to joining CR, Mr. Jeuter was the
pharmaceutical analyst for REDG Securities , an underwriter for IRTP,
manufacturer of Druti. During his stay at REDG, Mr. Jeuter was consistent
in issuing strong buys for Vivus. Since 02. 11. 21, VVUS has lost 75% of
its value.

Sven Weyman (Jérôme Flickschuh): Jérôme Flickschuh is the underwriter for
Vivus. Similar to Otmar Jeuter, Mr.Willmanns has strongly recommended VVUS.

Victor Vanderliek (Wehedy): Wäschetruhe own 4.1% of VVUS

------ clip ------

Kann ja manchmal ganz interessant sein, solche Sachen zu kennen ;-)

Beste Größe

Orlando